Wake Forest University

Carla Lema Tome

Waldemar Debinski

Sara Ferluga

Poonam S Sonawane

Provided herein is a construct comprising, in combination: an EphA3, EphA2 and/or EphB2 binding ligand; and at least one effector molecule. In some embodiments, the at least one effector molecule comprises a therapeutic agent, a nanoparticle, a detectable group, a lipid, or a liposome. In some embodiments, the construct is a fusion protein and/or a covalent conjugate. Further provided is a construct comprising, in combination: a ligand that binds to EphA2, EphA3 and/or EphB2; a ligand that binds to IL-13R&#x3b1;2; and at least one effector molecule. Also provided are methods of use thereof for treating cancer.

EPHA3 and multi-valent targeting of tumors

Provided herein is a construct comprising, in combination: an EphA3, EphA2 and/or EphB2 binding ligand; and at least one effector molecule. In some embodiments, the at least one effector molecule comprises a therapeutic agent, a nanoparticle, a detectable group, a lipid, or a liposome. In some embodiments, the construct is a fusion protein and/or a covalent conjugate. Further provided is a construct comprising in combination: a ligand that binds to EphA2, EphA3 and/or EphB2; a ligand that binds to IL-13R&#x3b1;2; and at least one effector molecule. Also provided are methods of use thereof for treating cancer.

Growing community of inventors

Winston-Salem, NC, United States of America

Carla Lema Tome